Q-omics provides the consensus-scored PRAC2 profile across patient tissues and cancer cell-line models. PRAC2 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, PRAC2 is differentially expressed in 13, with the highest sampling consensus in STAD. Additionally, PRAC2 RNA expression shows 10,692 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UCS, STAD, and TGCT as cancer lineages where PRAC2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRAC2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRAC2 survival associations across molecular data types. PRAC2 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRAC2 RNA expression–survival associations across cancer types. High PRAC2 expression shows unfavorable associations in ACC, BRCA, KIRC, LGG and THYM, but favorable associations in UCS. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify UCS as the clearest survival context for PRAC2 RNA expression.
This table summarizes PRAC2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for PRAC2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRAC2 shows higher tumor expression in STAD, HNSC, UCEC, BRCA, KIRC and KIRP. The STAD box plot shows higher PRAC2 RNA expression in tumor versus normal tissue (log2 FC = +1.039, t-test p < 0.001).
This table shows molecular features associated with PRAC2 in patient tissues and cancer cell lines. In patient samples, PRAC2 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, PRAC2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE.
